Document QXmwXmoOmXw1kMdKaM9YwqDp5

Kathrrhw E.R e d , Ph.D. Staff Vice President a8 4 3M Eaviroamemt4 He8ltb rod Saftty oper8tlolrr 900 Bush Avenue. Building 42-2E-26 Po Box 33331 St. Paul, MN 55133-3331 651 778 4331 February 24,2004 Documentproctsslngcenter EPA East -Room 6428 Attn. Saction we) Offica of Pollution prevepltion and Toxics US EPA 1200PermsylvaniaAv~NW WashingtOnDc 20460-0001 Re: TSCA 8(E) SUPPLEMENTAL SUBMISSION Docket No. 8BHQ-1180-373 Dear sirs: 3M has received h a l re~ultfsir a n ~ p h a n n a c os~tudcy hratsconductedwith p&-yl fldd (POSF, C A M307-35-7) indicating that the test substance metabolizes to pcrfl-e sulfbnate(PFOS,CAW 2795-39-3). . . The study was umductcd by 3M's Strategic Toxiwlogy Ldxmtmy. A single oral doseof 5 mgkgPOSF was aAmtnlstlroAto 15malera.t~N. ecxupsi~werepeafirnned on days 1,4, and 29 post dose. The studyresultrr indicate that POSFwas metabolized to PFOS. Maximum PFOS in the liver occurred on day 4 poet dose at approximately llppm,orlos/oofthedosa. Ondayo1and29postdosc,thcPF0Swncentration~ the liverwas 7 and 4 ppm,~ v t s l y . POSF wasused as anintennediategas hanisolatedhdus&hlprocesa to produce PFOS and related products 3M no longer maaufactures POSF. EacIosad please find the final study titled kinetic study of Pd-day1 Flwride (POSF) Following a Single OEal Gavage Dose in Rats." Please contact Andrew Seacat (651-575-3161) ifyou have any Questionsor ifwe can provide additional informatian. Sincerely, n r Staffvice President Environmental, Health and SaWy Opcratiws Ellclosure